Used to treat serious bacterial infections caused by Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). It is indicated for complicated skin and skin structure infections (cSSSI) and hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) when alternative treatments are not suitable. Telavancin hydrochloride is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis and disrupts cell membrane integrity, allowing for once-daily intravenous dosing, which improves clinical management in hospital settings. It is also under investigation for activity against other multidrug-resistant bacterial strains, making it a valuable option in combating antimicrobial resistance.